Abstract
Objective: A recent transposon mutagenesis screen has identified the Zmiz1 gene as a new potential oncogene in carcinomas of the skin. It is well known that mutations of the p53 tumor suppressor gene are the most common genetic alterations in epithelial ovarian cancer. Previous studies have shown that Zmiz1 appears to transcriptionally regulate the p53 gene. There are no studies that evaluate Zmiz1expression and alterations in the p53 gene in gynecologic malignancies, specifically epithelial ovarian cancer. We hypothesize Zmiz1 expression is elevated in epithelial ovarian tumors and there is an interaction between Zmiz1 and the p53 tumor suppressor gene in ovarian tumors.
Highlights
Included in the analysis were sixty-one patients diagnosed with epithelial ovarian cancer
Immunostaining for the Zmiz1 protein was performed with the following results: 17 (28%) tumors were positive, 11 (18%) tumors had equivocal staining, 1Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, 2Department of Anatomy and Cell Biology, 3Department of Pathology, 4Holden Comprehensive Cancer Center, 5Department of Biostatistics, The University of Iowa, Iowa City, Iowa 52242
Of the tumors with positive Zmiz1 staining, 13/17 (76%) had p53 gene mutations (p=0.03)
Summary
Zmiz is Overexpressed in Epithelial Ovarian Cancer and Associated with p53 Gene Mutations. MD, Laura Rogers, BS, Megan Samuelson, MD, Traci Neff, BS, David P. MD, Amina Ahmed, MD, Koen DeGeest, MD, Anna Button, MS, Adam Dupuy, PhD, Michael J.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.